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Abstract
Background: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an effective treatment
in acute ischemic stroke. However, IVT is contraindicated when blood pressure is above 185/110 mmHg, because of an
increased risk on symptomatic intracranial hemorrhage. In current Dutch clinical practice, two distinct strategies are
used in this situation. The active strategy comprises lowering blood pressure with antihypertensive agents below these
thresholds to allow start of IVT. In the conservative strategy, IVT is administered only when blood pressure
drops spontaneously below protocolled thresholds. A retrospective analysis in two recent stroke trials showed
a non-significant signal towards better functional outcome in the active group; robust evidence for either
strategy, however, is lacking. We hypothesize that (I) the active strategy leads to a better functional outcome
three months after acute ischemic stroke. Secondary hypotheses are that this effect occurs despite (II)
increasing the number of symptomatic intracranial hemorrhages, and could be attributable to (III) a higher
rate of IVT treatments and (IV) a shorter door-to-needle time.
Methods and design: The TRUTH is a prospective, observational, cluster-based, parallel group follow-up
study; in which participating centers continue their current local treatment guidelines. Outcomes of patients
admitted to centers with an active will be compared to those admitted to centers with a conservative strategy. The
primary outcome is functional outcome on the modified Rankin Scale at three months. Secondary outcomes are
symptomatic intracranial hemorrhage, IVT treatment and door-to-needle time. We based our sample size estimate on
an ordinal analysis of the mRS with the “proportional odds” model. With the aforementioned signal observed in a
recent retrospective study in these patients as an estimate of the effect size and with alpha 0 · 05, this analysis would
have an 80 % power with a total number of 600 patients. Corrections for expected imbalance in group size and
clustering effects resulted in a sample size of 1235 patients.
Discussion: The TRUTH is the first large prospective study specifically studying IVT-candidates with elevated blood
pressure, and has the potential to change clinical practice and optimize acute stroke care in these patients.
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Background
Elevated pre-treatment blood pressure
Intravenous thrombolysis (IVT) with recombinant tissue
plasminogen activator (rtPA) is an effective treatment
for acute ischemic stroke [1]. Unfortunately, the number
of stroke patients treated with rtPA is still limited [2].
One of the main reasons that patients are withheld IVT
is a pre-treatment blood pressure (BP) above systolic BP
of 185 mmHg or a diastolic BP > 110 mmHg. These BP
thresholds were introduced in the National Institute of
Neurological Disorders and Stroke (NINDS) rtPA Stroke
Study [3], and were based on pilot studies in which high
diastolic BP levels were associated with an increased risk
of symptomatic intracerebral hemorrhage (sICH) after
treatment with rtPA [4]. In a recent post-hoc analysis in
the PRomoting ACute Thrombolysis in Ischemic StrokE
(PRACTISE) [5] trial and the Preventive Antibiotics in
Stroke Study (PASS) [6], the prevalence of elevated pre-
treatment BP in patients otherwise eligible for IVT was
substantial: 20 % [7], which is similar to that in a previ-
ous retrospective study [8].
Treatment strategies (active vs. conservative)
In current Dutch clinical practice, and according to na-
tional guidelines, neurologists can use two distinct strat-
egies in managing elevated pre-treatment BP in patients
otherwise eligible for IVT [9].
The first strategy is active BP lowering with antihyper-
tensive agents, aiming to lower BP below the thresholds to
allow IVT. This strategy is in line with recommendations
in current international guidelines that BP should be care-
fully lowered in these patients (Class of evidence: Class IV
[10], and Level of Evidence B [11]). However, these recom-
mendations are based on expert opinion only, and several
critical remarks can be made regarding this strategy. First,
patients with elevated pre-treatment BP were included in
the larger IV rtPA trials only if they reached BP thresholds
with oral or sublingual antihypertensive medication (e.g.
NINDS [3], ATLANTIS [12] and ECASS-III [13]). There-
fore, little is known about the efficacy and safety of IVT in
patients who require intravenous antihypertensive medi-
cation. Secondly, despite lowering BP below IVT thresh-
olds, the risk on sICH could still be increased. Indeed, one
retrospective study found an increased relative risk of 2 ·
47 (95 % confidence interval, 1 · 15 to 5 · 28) on sICH in
patients treated for elevated pre-treatment BP [14]. Two
similar studies found similar results but the associations
were not statistically significant [15, 16]. Because all three
studies were retrospective and relatively small (n = 510,
427 and 178 respectively), it is difficult to draw any sound
conclusions. Finally, iatrogenic BP lowering in a state of
failing cerebral autoregulation could compromise perfu-
sion of the already ischemic penumbra, with subsequent
neurological deterioration [17].
The second strategy concerning pre-treatment increased
blood pressure is to measure and wait if the blood pres-
sure drops spontaneously. This avoids the possible disad-
vantages of active BP lowering as mentioned above and is
current clinical practice in several Dutch centers, despite
international guidelines that advocate an active strategy.
In these centers antihypertensive agents are not routinely
administered, and IVT is administered only when the BP
drops spontaneously below the recommended thresholds.
The major disadvantage of this strategy is that fewer pa-
tients end up being treated with IVT, when there is no
spontaneous decrease in BP [7]. Another disadvantage
could be an increase of the door-to-needle time (DNT)
while waiting for a spontaneous drop in BP, while an ac-
tive strategy is associated with only a modest increase in
the DNT [18]. However, in a recent study this increase in
DNT was not found [7].
Clinical practice
In contrast to other European countries, Dutch stroke
guidelines do not recommend active lowering of blood
pressure to date. In order to clarify current clinical prac-
tice, and in order to legitimize the proposed trial, we per-
formed an online questionnaire among vascular
neurologists in Dutch centers administering IVT. Ques-
tionnaires were sent to neurologists in 81 centers and 75
responded (93 %). Of these, 51 (68 %) reported to use an
active – and 17 (23 %) a conservative strategy. The
remaining 7 centers reported not to have a uniform strat-
egy (unpublished data).
Aim
The aim of our study is to elucidate whether we should




We hypothesize that in patients with a pre-treatment BP
above 185/110 mmHg and otherwise eligible for IVT an
active BP lowering strategy leads to [1] a better func-
tional outcome at three months than a conservative
watch and wait strategy. Secondary hypotheses are that
this effect occurs despite [2] increasing the proportion of
symptomatic intracranial hemorrhages, and could be at-
tributable to [3] a higher rate of IVT treatments and [4]
a shorter door-to-needle time.
Design
The ThRombolysis in UnconTrolled Hypertension
(TRUTH) is an observational, prospective, multicenter,
cluster-based, parallel group follow-up study.
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Patient population
All adult ischemic stroke patients with elevated pre-
treatment BP as the only contraindication to delay or
withhold treatment with IVT.
Treatment strategy
Participating centers will continue their current local treat-
ment guideline (either active or conservative strategy). Both
the active and conservative strategy have to be formalized
in local guidelines, and have to be endorsed by all neurolo-
gists executing acute stroke care. These local guidelines do
not have to match specific preset criteria, for example
regarding route of administration or dosage schemes of
antihypertensive agents. Centers are allowed to change
their strategy during the course of the study. Patients
will receive either strategy, depending on to which cen-
ter they are admitted.
Intra-arterial therapy
Treatment with intra-arterial therapy (IAT) is not an ex-
clusion criterion, and in all our analyses we will adjust for
this factor. Patients receiving IAT without prior IVT be-
cause of elevated BP are also eligible for the TRUTH study
as the same contra-indication applies for these patients.
Eleven of the 36 participating centers are currently per-
forming IAT, and ten of these use an active treatment strat-
egy. However, patients enrolled in non-interventional
centers eligible for IAT are likely to be referred to an inter-
vention center. Therefore, we expect no major difference in
the number of patients receiving IAT between both groups.
Outcome measures
The primary outcome is the functional outcome on the
modified Rankin Scale (mRS) at 90 days assessed with a
telephone interview by trained research nurses blinded
for the treatment strategy. Secondary outcomes are
symptomatic intracranial hemorrhage (sICH), defined as
any CT-documented hemorrhage accompanied by clin-
ical deterioration identified as ≥ 4 points increase on the
NIHSS compared with the best recorded NIHSS since
admission (ECASS II criteria) [19], the rate of patients
receiving IVT, and the door-to-needle time recorded as
recently defined by Kruyt et al. [20].
Statistical analysis
The primary analysis will be an ordinal analysis of the
seven categories on the mRS, by means of the propor-
tional odds model [21]. In this model, it is assumed that
the odds ratio is proportional across all possible dichoto-
mization levels of the ordinal outcome, which will be for-
mally tested with Rao’s score test. To produce an effect
estimate (odds ratio with corresponding 95 % confidence
interval (CI)) and to allow for covariate adjustment, or-
dinal logistic regression will be used. Secondly, to assess
internal consistence, two fixed dichotomous analyses of
the outcome on the mRS will also be performed (good
outcome 0–1 vs. poor outcome 2–6, and favorable out-
come 0–2 vs. unfavorable 3–6). Secondary outcomes will
be analyzed in a Poisson regression analysis (binary out-
come; sICH, IVT) or linear regression analysis (continu-
ous outcome; DNT). IVT and sICH rates will be reported
as percentages with 95 % CIs, DNTs will be reported as
mean with standard deviation or median with interquartile
range depending on its distribution.
Sample size estimates
We based our sample size on the ordinal analysis of the
mRS. With the increase in favorable outcome in the ac-
tive group in the post-hoc analysis as an estimate of the
effect size and with alpha 0 · 05, this analysis will have a
power of 80 % if we include 600 patients. The distribu-
tion between both groups will not be equal; we esti-
mated a ratio of 3:1 in favor of the active strategy based
on our aforementioned questionnaire. Since such a dis-
tribution leads to a 1 · 33 fold increase of the sample size
in a regular chi-square test, we also applied this factor to
our sample size estimate, resulting in an estimate of 798
patients.
Because of presumed similarity among patients within
preexisting clusters, the variability in response and the
power to detect true differences between arms are re-
duced in a clustered sample. We used the formula by
Kerry and Bland to correct for this clustering effect [22]:
DE ¼ 1þ ρ cv2 þ 1 m‐1 
The design effect (DE) is the factor that is ultimately
applied to a standard sample size estimate to correct
for the clustered design. First, we need to estimate the
intracluster coefficient (ρ), which is reflected by the ra-
tio of the variance of a certain variable between and
within clusters. With this intracluster coefficient, the
mean number of patients per cluster (m), and the coef-
ficient of variation in cluster size (cv, to correct for im-
balances in cluster size) [23], the DE is estimated. We
used an intracluster coefficient of 0.015 in our calcula-
tion. This number was derived from the multicenter
cluster-randomized PRACTISE trial [5], in which an
ICC of 0.0154 was calculated using their outcome on
thrombolysis percentages from 12 Dutch hospitals. We
estimated the cv to be 0.50, based on a similar ob-
served coefficient in a study with cluster characteristics
comparable to those we expect in our study [24]. Fur-
thermore, we estimate the mean number of patients
per cluster to be 30. With these estimations, our de-
sign effect is 1.5475 and therefore our effective sample
size will be 798 patients with an actual sample size of
1235 patients.
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Feasibility
In the Netherlands, 3760 patients in 86 hospitals were
treated with IVT in 2012 [25]. Therefore, we estimate
that elevated pre-treatment BP occurs in at least 750
IVT patients per year. In our aforementioned post-hoc
analysis, we identified 231 patients with elevated pre-
treatment BP of whom 149 received IVT. Therefore, our
best estimate of the number of patients in the
Netherlands with elevated pre-treatment BP is 1163 per
year (231 × 750 / 149).
We estimate the mean number of patients subjected
to IVT per participating center per year to be 50. There-
fore, in the average center, elevated pre-treatment BP
will occur at least 10 times each year. If we include pa-
tients for 4 consecutive years, we need 31 centers to par-
ticipate. As treatment allocation is determined by center,
refusal to participate on patients level will be negligible.
A list of participating centers and local investigators is
supplied in Appendix 1: Executive team.
Discussion
Elevated pre-treatment blood pressure (BP) is the most
common potentially modifiable contraindication for
intravenous thrombolysis (IVT). Current international
guidelines recommend administering antihypertensive
agents in order to lower BP below IVT thresholds. How-
ever, this recommendation is based on relatively small,
retrospective studies that only report symptomatic intra-
cranial hemorrhage (sICH) as outcome. In contrast to
other European countries, Dutch stroke guidelines do
not recommend active lowering of blood pressure to
date. In most Dutch centers antihypertensive agents are
administered (active strategy), whereas in other centers
they are not (conservative strategy). In an international
Delphi study on contraindications for IVT, no consensus
was reached concerning BP management [26]. In our
opinion, it remains therefore unclear whether patients
with elevated pre-treatment BP should be actively
treated with antihypertensive agents or not. The TRUTH
study is the first large prospective study specifically de-
signed to elucidate this clinical question.
Following up on the post-hoc analysis in PRACTISE [5]
and PASS [6], which revealed a non-significant trend to-
wards better functional outcome in patients subjected to
an active treatment strategy, several design options for
further study on this clinical question were considered. A
randomized design, with randomization either at patient
level or at center level, was considered first. However, we
deemed this to be unfeasible. Randomization at patient
level would be highly susceptible to selection bias, as most
treating physicians have a strong preference towards a cer-
tain strategy and would therefore be prone to only include
specific patients. Besides, in this hyper acute setting where
time is of essence, acquiring patient consent for
randomization would cost too much time. Randomization
at cluster level was deemed unfeasible, as most centers
have formulated their treatment strategies in local guide-
lines and would be unwilling to participate in a trial that
would allocate their center randomly to a either strategy.
An observational design is feasible because of the differ-
ent treatment strategies used in Dutch clinical practice. In
some centers, where no uniform strategy was yet defined,
one of both strategies was adopted in order to participate
in the study. Because of the small number of Dutch cen-
ters administering IVT in which no uniform strategy was
defined (7 out of 75 in our questionnaire) and the possibil-
ity to participate in this study after adopting a uniform
strategy, we judge the possibility of selection bias on cen-
ter level to be very low. The observational design also
allowed us to start relatively fast with subject enrollment,
an important pragmatic argument in a field moving stead-
ily towards the active strategy despite lack of evidence.
Furthermore, we expect that our design results in a much
higher participation rate at center level and a higher en-
rollment rate at patient level in comparison with a ran-
domized design.
As a safety endpoint we used the ECASS-II definition
of sICH (any CT-documented hemorrhage accompanied
by clinical deterioration identified as ≥ 4 points increase
on the NIHSS compared with the best recorded NIHSS
since admission). We used this definition because a re-
cent study judged it to be more clinically relevant than
most other definitions, in terms of its ability to identify
hemorrhages that alter functional outcome three months
after acute ischemic stroke [27].
We considered an ordinal analysis of the modified Rankin
Scale (mRS) preferable to a binary (dichotomized) analysis
for two reasons: First, an ordinal analysis is more efficient
in models with a treatment effect present over the entire
range of the outcome scale (as we expect in our study); be-
cause it retains all information captured by the outcome
scale, an ordinal analysis improves study power in such
models [28]. Secondly, multiple underlying mechanisms of
an active strategy treatment effect might be present simul-
taneously (higher IVT rate, shorter door-to-needle time,
higher sICH rate, iatrogenic penumbral hypoperfusion),
and these could express themselves in different directions
in different parts of the mRS spectrum. An ordinal analysis
is therefore especially appropriate as it captures shifts in
both directions (efficacy and safety) in a single analysis [29].
Overall, the TRUTH study is designed to improve clin-
ical practice and optimize acute stroke care in IVT can-
didates with elevated blood pressure.
Trial status
Recruitment started in April 2015 and is ongoing
(85 participants recruited as of November 1st, 2015).
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Ethics
Written informed consent will be obtained from each
patient or legal representative. The patient information
describes the purpose and design of the study, and
the procedures for recording clinical information and
3-month follow-up. Collection of consent and study
enrollment do not have to be done before either treatment
strategy is carried out, since the strategy in question is
standard of practice in that center. The study protocol, pa-
tient information and enrollment procedure were assessed
and approved by the Medical Ethics Committee and Re-
view Board of the Academic Medical Center in
Amsterdam. Local scientific and ethical committees of
each participating center will perform further assessments
of local feasibility.
Appendix 1: TRUTH Investigators
Principal investigators: N.D. Kruyt, MD PhD; P.J.
Nederkoorn, MD, PhD.
Steering committee: A. Algra, MD, PhD; D.W.J. Dip-
pel, MD, PhD; L.J. Kappelle, MD, PhD; R.J. van Oosten-
brugge, MD, PhD; Y.B.W.E.M. Roos, MD, PhD; M.J.
Wermer, MD, PhD; H.B. van der Worp, MD, PhD.
Participating centers (local investigator) as of Novem-
ber 2015: Active: Leiden University Medical Center, Lei-
den (N.D. Kruyt); Erasmus University Medical Center,
Rotterdam (D.W.J. Dippel); University Medical Center
Utrecht, Utrecht (H.B. van der Worp); Maastricht Uni-
versity Medical Center Plus, Maastricht (R.J. van Oos-
tenbrugge); Admiral de Ruyter Hospital, Goes (E.W.
Peters); Atrium Medical Center, Heerlen (A. Schreuder);
Bethesda Hospital, Hoogeveen (J.H. Kwant); Elkerliek
Hospital, Helmond (G.S. Grooters); Hospital Gelderse
Vallei, Ede (J.M.P. Rovers); Groene Hart Hospital, Gouda
(K. de Gans); Maasstad Hospital, Rotterdam (R. Saxena);
Maxima Medisch Centrum, Eindhoven (B.C.A.M. van Gin
neken); Medical Center Haaglanden Westeinde, The Hague
(K. Jellema); Medical Center Leeuwarden, Leeuwarden
(W.J. Schuiling); Medisch Spectrum Twente, Enschede
(P.J.A.M. Brouwers); Radboud UMC, Nijmegen (E. Rich-
ard); Reinier de Graaf Gasthuis, Delft (L.A.M. Aerden);
Rijnland Hospital, Leiderdorp (E.L.L.M. de Schryver); Rijn-
state, Arnhem (S.E. Vermeer); St. Elisabeth Hospital, Til-
burg (J.H. van Tuijl); St. Franciscus Hospital, Rotterdam
(F.H. Vermeij); St. Jans Gasthuis, Weert (H. Lövenich);
Hospital St. Jansdal, Harderwijk (A. Bijl-van Dijk); Sloter-
vaart Hospital, Amsterdam (F.H.M. Spaander); VieCuri,
Venlo (A.M.H.G. van der Heijden); Vlietland Hospital,
Schiedam (C.L. Alblas). Conservative: Academic Medical
Center Amsterdam, Amsterdam (P.J. Nederkoorn); Albert
Schweitzer Hospital, Dordrecht (H. Kerkhoff); Kennemer
Gasthuis, Haarlem (F. de Beer); Rode Kruis Hospital, Bever-
wijk (W.D.M. van der Meulen); VU University Medical
Center, Amsterdam (M.C. Visser); Medical Center Alkmaar,
Alkmaar (P. Halkes); Onze Lieve Vrouwe Gasthuis,
Amsterdam (V.I.H. Kwa); St. Lucas Andreas Hospital,
Amsterdam (R.M. van den Berg – Vos); Tergooiziekenhui-
zen, Hilversum (J.R. de Kruijk); Westfriesgasthuis, Hoorn
(T.C. van der Ree).
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